GDNF and amyotrophic lateral sclerosis: The aim of another glia-based clinical trial (trial # ID: NCT02943850) is the safety of transplanting neural progenitor cells that have been engineered to produce a glial cell line-derived neurotrophic factor (GDNF) into the spinal cord of ALS patients to promote the survival of of neuronal cells.